首页> 外文期刊>Molecular cancer therapeutics >A687V EZH2 Is a Driver of Histone H3 Lysine 27 ( H3K27) Hypertrimethylation
【24h】

A687V EZH2 Is a Driver of Histone H3 Lysine 27 ( H3K27) Hypertrimethylation

机译:A687V EZH2是组蛋白H3赖氨酸27(H3K27)超三甲基化的驱动器

获取原文
获取原文并翻译 | 示例
       

摘要

The EZH2 methyltransferase silences gene expression through methylation of histone H3 on lysine 27 (H3K27). Recently, EZH2 mutations have been reported at Y641, A677, and A687 in non-Hodgkin lymphoma. Although the Y641F/N/S/H/C and A677G mutations exhibit clearly increased activity with substrates dimethylated at lysine 27 (H3K27me2), the A687V mutant has been shown to prefer a monomethylated lysine 27 (H3K27me1) with little gain of activity toward H3K27me2. Herein, we demonstrate that despite this unique substrate preference, A687V EZH2 still drives increased H3K27me3 when transiently expressed in cells. However, unlike the previously described mutants that dramatically deplete global H3K27me2 levels, A687V EZH2 retains normal levels of H3K27me2. Sequencing of B-cell-derived cancer cell lines identified an acute lymphoblastic leukemia cell line harboring this mutation. Similar to exogenous expression of A687V EZH2, this cell line exhibited elevated H3K27me3 while possessing H3K27me2 levels higher than Y641-or A677-mutant lines. Treatment of A687V EZH2-mutant cells with GSK126, a selective EZH2 inhibitor, was associated with a global decrease in H3K27me3, robust gene activation, caspase activation, and decreased proliferation. Structural modeling of the A687V EZH2 active site suggests that the increased catalytic activity with H3K27me1 may be due to a weakened interaction with an active site water molecule that must be displaced for dimethylation to occur. These findings suggest that A687V EZH2 likely increases global H3K27me3 indirectly through increased catalytic activity with H3K27me1 and cells harboring this mutation are highly dependent on EZH2 activity for their survival. (C)2014 AACR.
机译:EZH2甲基转移酶通过组蛋白H3在赖氨酸27(H3K27)上的甲基化使基因表达沉默。最近,在非霍奇金淋巴瘤的Y641,A677和A687处报道了EZH2突变。尽管Y641F / N / S / H / C和A677G突变在赖氨酸27(H3K27me2)处被二甲基化的底物表现出明显增强的活性,但已显示A687V突变体偏向于单甲基化赖氨酸27(H3K27me1),而对H3K27me2的活性几乎没有增加。在本文中,我们证明了尽管有这种独特的底物偏好,但当在细胞中瞬时表达时,A687V EZH2仍然驱动增加的H3K27me3。但是,与先前描述的突变体显着耗尽全局H3K27me2水平不同,A687V EZH2保留了正常水平的H3K27me2。 B细胞衍生的癌细胞系的测序确定了具有这种突变的急性淋巴细胞白血病细胞系。与A687V EZH2的外源表达相似,该细胞系表现出升高的H3K27me2,而其H3K27me2水平高于Y641或A677突变株。用选择性EZH2抑制剂GSK126治疗A687V EZH2突变细胞与H3K27me3的总体下降,基因的稳定激活,胱天蛋白酶的激活和增殖的降低有关。 A687V EZH2活性位点的结构模型表明,H3K27me1催化活性的提高可能是由于与活性位点水分子的相互作用减弱,必须将其置换才能发生二甲基化。这些发现表明,A687V EZH2可能通过增加对H3K27me1的催化活性而间接增加了整体H3K27me3,而具有此突变的细胞则高度依赖EZH2活性来生存。 (C)2014 AACR。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号